HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Values Beauty, Supplement Sectors As It Considers Leaving Others

Executive Summary

Unilever reported 0.5% full-year sales growth for the beauty and personal care division to 5.6bn and overall growth was 2.9% to 52bn, but the fourth quarter was its weakest in more than a decade, with reported sales growth at 1.5% to 12.6bn.

You may also be interested in...



Unilever To Slim Down Further With Ice Cream Separation

Unilever's ‘Fewer Things Better’ Growth Action Plan is in motion as the London-based company announces plans to separate out its Ice Cream division to accelerate growth and achieve cost savings of around €800m over the next three years.

Unilever Targets Hair Health From Inside-Out With Nutrafol Acquisition

After five years with a minority interest in Nutrafol for “clinically proven hair growth,” Unilever will acquire a majority stake in the supplements brand under undisclosed terms. Nutrafol says its nutraceuticals for men and women – sold through multiple channels including by more than 3,000 physicians – target “the six root causes affecting hair health.”

Unilever’s Post-Crisis Outlook: Consumers Will Trade Down, Stay Online In Global Recession

Unilever is not providing fiscal 2020 guidance at the moment amid so many COVID-19 unknowns. However, leadership did offer predictions during the firm’s first-quarter earnings call as to how the pandemic is likely to have lasting effects on consumer behavior and the global marketplace.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel